SA¹ú¼Ê´«Ã½

Tuesday 22 October 2024
Salisbury Foundation Trust

FOI_8185

Internal Reference Number: FOI_8185

Date Request Received: 01/10/2024 00:00:00

Date Request Replied To: 09/10/2024 00:00:00

This response was sent via: By Email

Request Summary: new biologic and targeted medications within dermatology

Request Category: Researcher

 
Question Number 1:
How many patients were treated in September 2024 (or latest available month) by the Dermatology department with the following drugs:

• Abrocitinib (Cibinqo)

• Baricitinib (Olumiant)

• Dupilumab (Dupixent)

• Lebrikizumab (Ebglyss)

• Omalizumab (Xolair)

• Tralokinumab (Adtralza)

• Upadacitinib (Rinvoq)

 
Answer To Question 1:
• Abrocitinib (Cibinqo) <5

• Baricitinib (Olumiant) 0

• Dupilumab (Dupixent) 25

• Lebrikizumab (Ebglyss) 0

• Omalizumab (Xolair) 5

• Tralokinumab (Adtralza) <5

• Upadacitinib (Rinvoq) <5

 
To return to the list of all the FOI requests please click here

Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

SA¹ú¼Ê´«Ã½, SA¹ú¼Ê´«Ã½ Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 SA¹ú¼Ê´«Ã½
Trust Values